证券代码：603102 证券简称：百合股份 公告编号：2026-001 威海百合生物技术股份有限公司 关于董事会延期换届的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 威海百合生物技术股份有限公司（以下简称"公司"）第四届董事会将于 2026 年 1 月 15 日届满。鉴于相关换届工作尚在积极筹备中，为保证公司董事会 相关工作的连续性，公司董事会换届将适当延期，董事会各专门委员会、高级管 理人员的任期亦相应顺延。 在新一届董事会换届选举工作完成前，公司第四届董事会成员、第四届董事 会各专门委员会成员和高级管理人员将按照法律法规和《公司章程》等规定，继 续履行董事及高级管理人员的义务和职责。 公司董事会延期换届不会影响公司的正常运营。公司亦将积极推进相关工作， 尽快完成董事会的换届选举工作，并及时履行相应的信息披露义务。 特此公告。 威海百合生物技术股份有限公司董事会 2026 年 1 月 9 日 ...

Group 1 - The A-share market saw a broad increase in the food and beverage sector, with notable stocks such as Ziyan Food hitting the daily limit up [1] - Yangyuan Beverage approached the daily limit up, indicating strong investor interest and potential growth in the sector [1] - Other companies like Huanlejia and Qianwei Yangchu rose over 5%, while Baihe Co., Babi Food, and others increased by over 4%, reflecting a positive trend across multiple stocks in the industry [1]

根据国家统计局数据可知：2025年11月全国其他制造业出口货值为57.1亿元，同比下降4.3%；2025年1- 11月全国其他制造业累计出口货值为593.5亿元，累计同比增长4%。 2019年-2025年1-11月全国其他制造业出口货值统计图 上市公司：华纺股份（600448），凤竹纺织（600493），江南高纤（600527），浙文影业（601599）， 千禾味业（603027），广州酒家（603043），台华新材（603055），百合股份（603102），养元饮品 （603156），一鸣食品（605179），华生科技（605180），富春染织（605189），安德利（605198）， 佳禾食品（605300） 相关报告：智研咨询发布的《2026-2032年中国制造业市场竞争格局分析及投资发展研究报告》 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 ...

Group 1 - The core viewpoint of the report highlights the growth opportunities and landscape of China's nutrition and health industry, with a market size expected to reach 260.2 billion yuan by 2024, reflecting a CAGR of 6.3% from 2019 to 2024, indicating significant room for improvement in per capita consumption compared to countries like the US, South Korea, and Australia [1][20][19] - The demand side shows a trend towards "precise segmentation," driven by an aging population expanding the elderly health market, while Generation Z is emerging as a new consumer force due to increased health awareness [1][31][28] - The online channel dominates the distribution, with e-commerce expected to account for 60% of the market share by 2024, and platforms like Douyin experiencing rapid growth, achieving a 53% increase in sales [1][56][62] Group 2 - The category landscape presents a dual-track situation of "traditional steady growth and emerging explosive growth." The traditional category, particularly bone health, is growing at a rate of 18.4%, while new categories like oral anti-aging are projected to reach a market size of 65.4 billion yuan by 2024 [2][70] - The industry chain shows a fragmented competitive landscape at the downstream level, with small and medium brands entering quickly through online channels, while leading brands like Swisse maintain their position through a comprehensive brand matrix [2][10] - The report emphasizes the importance of product innovation and compliance advantages for leading companies like Xianle Health and Baihe Co., which are positioned to benefit from industry growth [2][10][19]

Group 1 - The Chinese health supplement industry is in a continuous expansion phase, driven by both evergreen and new consumer markets, with a retail scale expected to reach 260.2 billion yuan in 2024, reflecting a CAGR of 6.3% from 2019 to 2024 [2][9] - The per capita consumption of health supplements in China is only 26 USD, significantly lower than that in mature markets like the US and South Korea, indicating substantial room for penetration growth [2][29] - The consumer demographic is becoming younger and more diverse, with the 25-40 age group increasingly dominating the market, and a notable rise in consumption from lower-tier cities [2][31] Group 2 - Sales channels have evolved from direct sales and pharmacies to a diversified e-commerce model, with e-commerce accounting for 48.02% of sales in 2023, and live-streaming e-commerce penetration expected to reach 34.3% in 2024 [3][9] - Emerging brands are rapidly gaining market share through platforms like Douyin, which has seen significant sales growth in health supplements over the past three years [3][9] - The cross-border e-commerce sector is also growing, with flexible product entry mechanisms, and platforms like Douyin Global Purchase and Pinduoduo Global Purchase becoming mainstream channels [3][9] Group 3 - The contract manufacturing segment is expected to grow, with an estimated scale of approximately 3.4 billion USD in 2024, projected to reach 4 billion USD by 2027, reflecting a CAGR of 5.0% [3][9] - New consumer trends are driving demand for contract manufacturing, as emerging brands often adopt asset-light operational models, leading to increased demand for contract manufacturing services [3][9] - Major players like Xianle Health and Baihe Co. are positioned to benefit from this trend due to their research and scale advantages [3][10] Group 4 - Brand manufacturers are actively adjusting their product offerings and channel strategies to align with industry trends, focusing on innovative formulations and new sales channels [4][10] - Regulatory frameworks are becoming more standardized, with health supplements now subject to dual-track registration and filing management, promoting a more regulated and high-quality industry environment [4][10] - Companies are increasingly focusing on operational capabilities in marketing, channel management, and brand building to capture consumer interest and market share [4][10] Group 5 - The investment outlook suggests that the health supplement industry is poised for growth driven by channel shifts and emerging product categories, with contract manufacturers benefiting from increased demand [11] - Recommended focus on leading contract manufacturers with strong R&D capabilities and brand manufacturers that are adapting to new consumer trends and channel dynamics [11]

Investment Rating - The report maintains a "Strongly Outperform" rating for the health supplement industry [3] Core Insights - The health supplement market in China is expected to grow significantly, with a retail scale projected to reach 260.2 billion yuan by 2024, reflecting a CAGR of 6.3% from 2019 to 2024 [6][16] - The industry is characterized by a dual driving force from both mature markets and emerging consumer trends, with a notable shift towards younger demographics and new consumption patterns [22][40] - The contract manufacturing segment is anticipated to see increased concentration, benefiting from stable demand growth and the influx of new brands [2][8] Summary by Sections 1. Continuous Expansion of Health Supplements - The health supplement market is expanding, with the global market expected to reach 191.5 billion USD by 2024 [16] - The penetration rate of health supplements in China is significantly lower than in developed countries, indicating substantial growth potential [21][20] 2. Consumer Changes Driving Channel Transformation and Product Iteration - The primary sales channels for health supplements have shifted from direct sales and pharmacies to e-commerce, with e-commerce accounting for 48.02% of sales in 2023 [46] - The rise of live-streaming e-commerce has significantly contributed to the growth of the health supplement industry, with a penetration rate projected to reach 34.3% by 2024 [6][46] 3. Increased Concentration in the Contract Manufacturing Segment - The contract manufacturing segment is expected to benefit from the growing demand for health supplements, with major players like Xianle Health and Baihe Co. projected to capture significant market shares [2][7] - Brand owners are actively adapting to new trends, focusing on product innovation and channel diversification to capture market opportunities [8][7] 4. Investment Recommendations - The report suggests focusing on leading contract manufacturers with strong R&D capabilities and those that are well-positioned to benefit from emerging consumer trends [8] - Specific companies recommended for investment include Xianle Health and Baihe Co. in the contract manufacturing space, and H&H International Holdings and Tongrentang in the brand segment [8]

Core Insights - The Chinese nutrition and health market is experiencing continuous growth, with significant potential for per capita consumption improvement. The demand is driven by both aging populations and the younger Generation Z, evolving towards "precise segmentation" and functional foods [1][2]. Market Overview - The market size of China's nutrition and health food sector is projected to reach 260.2 billion yuan by 2024, with a CAGR of 6.3% from 2019 to 2024. Compared to countries like the US, South Korea, and Australia, there is still considerable room for per capita consumption growth [2]. - The aging population and increased health awareness are expanding the elderly health market, while social pressures and the rise of chronic diseases are making Generation Z a new consumer force in health products [2]. Channel Dynamics - Online channels dominate the market, expected to account for 60% of sales by 2024, an increase of 12 percentage points from 2021. Notably, Douyin (TikTok) is experiencing a growth rate of 53%, and cross-border channels are also seeing rapid expansion [3]. Product Categories - Traditional product categories are showing stable growth, with trends in large-scale production, innovation in dosage forms, and expansion of target demographics. The bone health market exemplifies traditional efficacy through ingredient innovation [4]. - Emerging categories are characterized by explosive growth from a small base, strong marketing attributes, and rapid iteration. Recent years have seen significant growth in oral beauty/anti-aging and probiotics, driven by star ingredients like ergothioneine and patented strains, leading to the emergence of new brands such as Feicui and Wonderlab [4]. Competitive Landscape - The downstream competitive landscape is fragmented, with many emerging functional food brands entering through online channels. Swisse maintains its leading position through targeted marketing and a comprehensive brand matrix [5]. - The expansion of industry demand and the entry of new light-asset brands present significant opportunities for midstream contract manufacturers. China's contract manufacturing rate remains lower than that of Europe and the US, with leaders like Xianle Health and Baihe Co. expected to enhance scale effects and benefit from industry growth [5]. - Recommended companies to watch include Jin Dawei, a leading supplier of health product raw materials; Jiyuan Group, focusing on muscle and joint health; Xianle Health, a global leader in nutrition and health contract manufacturing; Baihe Co., with a flexible supply chain and overseas acquisitions; H&H International Holdings, known for its strong brand and youthful positioning; and Kuntou Biological, a leading domestic probiotics company [5].

Group 1 - The core point of the article highlights that as of December 15, a total of 165 stocks in the Shanghai and Shenzhen markets have experienced net buying from main funds for five consecutive days or more [1] - The stock with the longest consecutive net buying days is Haohai Biological Technology, which has seen net buying for 15 consecutive trading days [1] - Other stocks with significant consecutive net buying days include Longteng Optoelectronics, China National Materials, Jianyan Institute, Xinhua Medical, Phoenix Shares, Huawang Technology, Hongdou Shares, and Baihe Shares [1]

威海百合生物技术股份有限公司（以下简称"公司"）于 2025 年 12 月 1 日召开第四届董事会第十五次会议，审议通过了《关于变更募集资金专项账户的 议案》，公司于近日已完成变更募集资金专项账户（以下简称"募集资金专户"） 并签署了《募集资金专户存储三方监管协议》，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2022]36 号文核准，本公司于 2022 年 1 月向社会公开发行人民币普通股（A 股）1,600.00 万股，每股发行价为 42.14 元，募集资金总额为人民币 67,424.00 万元，根据有关规定扣除发行费用 7,180.89 万元后，实际募集资金金额为 60,243.11 万元。该募集资金已于 2022 年 1 月到账， 上述资金到账情况业经容诚会计师事务所容诚验字[2022]251Z0001 号《验资报告》 验证，公司对募集资金采取了专户存储管理。后因证券登记费减免 6.40 万元， 实际发行费用较之前减少 6.40 万元，募集资金净额实际为 60,249.51 万元。 证券代码：603102 证券简称：百合股份 公告编号：2025-045 威海百合生物技术股份 ...

Core Viewpoint - The report highlights the export performance of China's other manufacturing sector, indicating a decline in export value in October 2025 while showing a slight cumulative growth for the year [1] Group 1: Company Performance - The listed companies include Huafang Co., Ltd. (600448), Fengzhu Textile (600493), Jiangnan High Fiber (600527), and others, indicating a diverse range of players in the manufacturing sector [1] - The report suggests that these companies may face challenges due to the overall decline in export values, particularly in the textile and food sectors [1] Group 2: Industry Statistics - In October 2025, the export value of the other manufacturing sector was 5.25 billion, representing a year-on-year decrease of 7.6% [1] - Cumulatively, from January to October 2025, the total export value reached 54.91 billion, with a year-on-year growth of 0.8% [1] - The data indicates a mixed performance in the manufacturing sector, with some months showing declines while others reflect growth [1]